整合原位免疫表达景观和基于基因表达的亚型来表征乳腺癌的异质性。

IF 3.4
Mustapha Abubakar, Hela Koka, Priscilla Ming Yi Lee, Hiu Yu Natalie Tang, Scott Lawrence, Karun Mutreja, Feng Wang, Cherry Wu, Koon-Ho Tsang, Yee-Kei Tsoi, W C Chan, Sze Hong Law, Ray Ka Wai Hung, Gary M K Tse, Kristine Jones, Aurelie Vogt, Maria Brown, Belynda D Hicks, Difei Wang, Bin Zhu, Lap Ah Tse, Xiaohong R Yang
{"title":"整合原位免疫表达景观和基于基因表达的亚型来表征乳腺癌的异质性。","authors":"Mustapha Abubakar, Hela Koka, Priscilla Ming Yi Lee, Hiu Yu Natalie Tang, Scott Lawrence, Karun Mutreja, Feng Wang, Cherry Wu, Koon-Ho Tsang, Yee-Kei Tsoi, W C Chan, Sze Hong Law, Ray Ka Wai Hung, Gary M K Tse, Kristine Jones, Aurelie Vogt, Maria Brown, Belynda D Hicks, Difei Wang, Bin Zhu, Lap Ah Tse, Xiaohong R Yang","doi":"10.1158/1055-9965.EPI-25-2068","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We previously identified three clinically relevant immune [i.e., low-tumor-infiltrating lymphocyte (TIL), high-TIL, and high-interferon-stimulated gene (ISG)] subtypes of luminal breast cancer using RNA sequencing in a cohort of women from Hong Kong. In this study, we evaluated whether standard, in situ immunohistochemistry (IHC), a more clinically accessible approach, could capture similar immune heterogeneity across intrinsic (PAM50) subtypes.</p><p><strong>Methods: </strong>In 148 patients with invasive breast cancer, we performed dual IHC staining for eight markers (CD3, CD8, CD20, FOXP3, CD68, CD163, PDL1, and IDO1) with pan-cytokeratin and quantified immune-positive cells in stromal regions by digital image analysis.</p><p><strong>Results: </strong>IHC marker expression strongly correlated with gene expression-based immune and intrinsic subtypes. Compared with luminal tumors classified as low-TIL, high-TIL tumors showed higher levels of CD3, CD8, CD20, PDL1, and IDO1. Similarly, high-ISG tumors expressed higher CD3, CD8, CD20, PDL1, and IDO1 than low-TIL tumors but were distinguished from high-TIL tumors by elevated CD163. Immune marker expression was generally higher in HER2-enriched and basal-like tumors than in luminal A and B tumors, though substantial variability existed within each subtype. Luminal B tumors expressed higher levels of CD3, CD8, CD20, and CD163 compared with luminal A tumors. Notably, immune infiltration was more strongly aligned with aggressive tumor features such as high grade, risk of recurrence scores, and TP53 mutations than with estrogen receptor/progesterone receptor expression.</p><p><strong>Conclusions: </strong>These findings confirm that subsets of luminal tumors harbor inflamed or macrophage-driven immune microenvironments.</p><p><strong>Impact: </strong>Parsimonious IHC panels can perform immune classification, supporting their potential utility in refining subtype stratification and informing clinical decision-making, particularly in resource-limited settings.</p>","PeriodicalId":520580,"journal":{"name":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","volume":" ","pages":"1358-1367"},"PeriodicalIF":3.4000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Integrating In Situ Immune Expression Landscape with Gene Expression-Based Subtyping to Characterize Breast Cancer Heterogeneity.\",\"authors\":\"Mustapha Abubakar, Hela Koka, Priscilla Ming Yi Lee, Hiu Yu Natalie Tang, Scott Lawrence, Karun Mutreja, Feng Wang, Cherry Wu, Koon-Ho Tsang, Yee-Kei Tsoi, W C Chan, Sze Hong Law, Ray Ka Wai Hung, Gary M K Tse, Kristine Jones, Aurelie Vogt, Maria Brown, Belynda D Hicks, Difei Wang, Bin Zhu, Lap Ah Tse, Xiaohong R Yang\",\"doi\":\"10.1158/1055-9965.EPI-25-2068\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>We previously identified three clinically relevant immune [i.e., low-tumor-infiltrating lymphocyte (TIL), high-TIL, and high-interferon-stimulated gene (ISG)] subtypes of luminal breast cancer using RNA sequencing in a cohort of women from Hong Kong. In this study, we evaluated whether standard, in situ immunohistochemistry (IHC), a more clinically accessible approach, could capture similar immune heterogeneity across intrinsic (PAM50) subtypes.</p><p><strong>Methods: </strong>In 148 patients with invasive breast cancer, we performed dual IHC staining for eight markers (CD3, CD8, CD20, FOXP3, CD68, CD163, PDL1, and IDO1) with pan-cytokeratin and quantified immune-positive cells in stromal regions by digital image analysis.</p><p><strong>Results: </strong>IHC marker expression strongly correlated with gene expression-based immune and intrinsic subtypes. Compared with luminal tumors classified as low-TIL, high-TIL tumors showed higher levels of CD3, CD8, CD20, PDL1, and IDO1. Similarly, high-ISG tumors expressed higher CD3, CD8, CD20, PDL1, and IDO1 than low-TIL tumors but were distinguished from high-TIL tumors by elevated CD163. Immune marker expression was generally higher in HER2-enriched and basal-like tumors than in luminal A and B tumors, though substantial variability existed within each subtype. Luminal B tumors expressed higher levels of CD3, CD8, CD20, and CD163 compared with luminal A tumors. Notably, immune infiltration was more strongly aligned with aggressive tumor features such as high grade, risk of recurrence scores, and TP53 mutations than with estrogen receptor/progesterone receptor expression.</p><p><strong>Conclusions: </strong>These findings confirm that subsets of luminal tumors harbor inflamed or macrophage-driven immune microenvironments.</p><p><strong>Impact: </strong>Parsimonious IHC panels can perform immune classification, supporting their potential utility in refining subtype stratification and informing clinical decision-making, particularly in resource-limited settings.</p>\",\"PeriodicalId\":520580,\"journal\":{\"name\":\"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology\",\"volume\":\" \",\"pages\":\"1358-1367\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2026-08-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1055-9965.EPI-25-2068\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-25-2068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:我们之前在香港的一组女性中使用RNA测序确定了三种临床相关的免疫(即低til,高til和高isg)亚型的腔内乳腺癌。在这里,我们评估了标准的原位免疫组织化学(IHC),一种更易于临床使用的方法,是否可以捕获内在(PAM50)亚型之间相似的免疫异质性。方法:148例浸润性乳腺癌患者,应用泛细胞角蛋白(pancytokeratin, PanCK)对8种标志物(CD3、CD8、CD20、FOXP3、CD68、CD163、PDL1、IDO1)进行双免疫组化染色,并利用数字图像分析定量基质区免疫阳性细胞。结果:IHC标志物的表达与基于基因表达的免疫亚型和内在亚型密切相关。与低til分类的管腔肿瘤相比,高til肿瘤显示更高的CD3、CD8、CD20、PDL1和IDO1水平。同样,高isg肿瘤比低tils表达更高的CD3、CD8、CD20、PDL1和IDO1,但通过CD163的升高与高tils区分开来。免疫标记物在her2富集和基底样肿瘤中的表达通常高于腔内A和腔内B,尽管每种亚型之间存在实质性的差异。与管腔A肿瘤相比,管腔B肿瘤表达更高水平的CD3、CD8、CD20和CD163。值得注意的是,与ER/PR表达相比,免疫浸润与侵袭性肿瘤特征(如高分级、复发风险评分和TP53突变)的相关性更强。结论:这些发现证实了腔内肿瘤亚群存在炎症或巨噬细胞驱动的免疫微环境。影响:简约的免疫组织免疫组可以进行免疫分类,支持其在改进亚型分层和为临床决策提供信息方面的潜在效用,特别是在资源有限的环境中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Integrating In Situ Immune Expression Landscape with Gene Expression-Based Subtyping to Characterize Breast Cancer Heterogeneity.

Background: We previously identified three clinically relevant immune [i.e., low-tumor-infiltrating lymphocyte (TIL), high-TIL, and high-interferon-stimulated gene (ISG)] subtypes of luminal breast cancer using RNA sequencing in a cohort of women from Hong Kong. In this study, we evaluated whether standard, in situ immunohistochemistry (IHC), a more clinically accessible approach, could capture similar immune heterogeneity across intrinsic (PAM50) subtypes.

Methods: In 148 patients with invasive breast cancer, we performed dual IHC staining for eight markers (CD3, CD8, CD20, FOXP3, CD68, CD163, PDL1, and IDO1) with pan-cytokeratin and quantified immune-positive cells in stromal regions by digital image analysis.

Results: IHC marker expression strongly correlated with gene expression-based immune and intrinsic subtypes. Compared with luminal tumors classified as low-TIL, high-TIL tumors showed higher levels of CD3, CD8, CD20, PDL1, and IDO1. Similarly, high-ISG tumors expressed higher CD3, CD8, CD20, PDL1, and IDO1 than low-TIL tumors but were distinguished from high-TIL tumors by elevated CD163. Immune marker expression was generally higher in HER2-enriched and basal-like tumors than in luminal A and B tumors, though substantial variability existed within each subtype. Luminal B tumors expressed higher levels of CD3, CD8, CD20, and CD163 compared with luminal A tumors. Notably, immune infiltration was more strongly aligned with aggressive tumor features such as high grade, risk of recurrence scores, and TP53 mutations than with estrogen receptor/progesterone receptor expression.

Conclusions: These findings confirm that subsets of luminal tumors harbor inflamed or macrophage-driven immune microenvironments.

Impact: Parsimonious IHC panels can perform immune classification, supporting their potential utility in refining subtype stratification and informing clinical decision-making, particularly in resource-limited settings.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书